ALEXANDRIA, MN - January 24, 2026 - PRESSADVANTAGE - Individuals living with or at risk for glaucoma in the region can ...

SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...

Despite updated understandings of IOP and glaucoma risk, cutoff values are still a primary influence on treatment ...

Glaucoma has long been treated as a plumbing problem of the eye, managed mainly by lowering pressure rather than protecting ...

Background/aims Up-to-date, stratified estimates of the number of individuals affected by glaucoma in the UK are lacking.

Researchers have predicted that cases of glaucoma, a common eye condition that can lead to blindness if not treated, are ...

If you were to listen to a day in the life of a veterinary ophthalmologist, you’d likely hear words and phrases you’ve never heard before. “A tubing system will be placed under your horse’s eyelid to ...

Researchers have identified a metabolically sensitive cell subtype in the eye's drainage system which shows early signs of ...

SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...

A trial shows minimally invasive nasal trabeculostomy can offer sustained IOP reduction and medication-free success in glaucoma.